Show simple item record

dc.contributor.authorLublin, Henrik
dc.contributor.authorHaug, Hans-Joachim
dc.contributor.authorKoponen, Hannu
dc.contributor.authorSigmundsson, Thordur
dc.contributor.authorKolb, Stefan A
dc.date.accessioned2010-06-15T14:59:16Z
dc.date.available2010-06-15T14:59:16Z
dc.date.issued2009
dc.date.submitted2010-06-15
dc.identifier.citationWorld J. Biol. Psychiatry. 2009, 10(4 Pt 3):710-8en
dc.identifier.issn1814-1412
dc.identifier.pmid18803070
dc.identifier.doi10.1080/15622970802269589
dc.identifier.urihttp://hdl.handle.net/2336/104880
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThe efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic treatment based on clinical judgement of the investigator. A total of 293 patients were randomized to 12 weeks treatment with either ziprasidone 80-160 mg/day (n=147) or with one of the comparator drugs (n=146). In the latter group the investigator could choose between olanzapine 10-20 mg/day (n=24), risperidone 4-8 mg/day (n=22) or quetiapine 300-750 mg/day (n=97). The study comprised four visits including a baseline examination prior to randomization and further examinations at the end of weeks 1, 4 and 12. Ziprasidone was non-inferior (defined as a difference of 7 units or less on the PANSS scale to the disadvantage of ziprasidone) to the composite group (olanzapine, risperidone or quetiapine) on the total PANSS score as well as on all subscores (P<0.0001); there were no significant between-group differences in the CGI-S and I and UKU scores. Ziprasidone-treated patients lost an average of 2.1 kg in the 12 weeks of the study, the mean weight for risperidone and quetiapine remained unchanged, and patients receiving olanzapine gained 3.1 kg on average.
dc.language.isoenen
dc.publisherInforma Healthcareen
dc.relation.urlhttp://dx.doi.org/10.1080/15622970802269589en
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAntipsychotic Agentsen
dc.subject.meshBenzodiazepinesen
dc.subject.meshCholesterolen
dc.subject.meshChronic Diseaseen
dc.subject.meshDibenzothiazepinesen
dc.subject.meshDrug Toleranceen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshPiperazinesen
dc.subject.meshProlactinen
dc.subject.meshRisperidoneen
dc.subject.meshSchizophreniaen
dc.subject.meshThiazolesen
dc.subject.meshTriglyceridesen
dc.subject.meshYoung Adulten
dc.titleZiprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trialen
dc.typeArticleen
dc.contributor.departmentPsychiatric University Center Glostrup, University of Copenhagen, Glostrup, Denmark. henlub01@glo.regionh.dken
dc.identifier.journalWorld journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatryen
html.description.abstractThe efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic treatment based on clinical judgement of the investigator. A total of 293 patients were randomized to 12 weeks treatment with either ziprasidone 80-160 mg/day (n=147) or with one of the comparator drugs (n=146). In the latter group the investigator could choose between olanzapine 10-20 mg/day (n=24), risperidone 4-8 mg/day (n=22) or quetiapine 300-750 mg/day (n=97). The study comprised four visits including a baseline examination prior to randomization and further examinations at the end of weeks 1, 4 and 12. Ziprasidone was non-inferior (defined as a difference of 7 units or less on the PANSS scale to the disadvantage of ziprasidone) to the composite group (olanzapine, risperidone or quetiapine) on the total PANSS score as well as on all subscores (P<0.0001); there were no significant between-group differences in the CGI-S and I and UKU scores. Ziprasidone-treated patients lost an average of 2.1 kg in the 12 weeks of the study, the mean weight for risperidone and quetiapine remained unchanged, and patients receiving olanzapine gained 3.1 kg on average.


This item appears in the following Collection(s)

Show simple item record